Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now

You can switch off notifications anytime using browser settings.
Stock Analysis, IPO, Mutual Funds, Bonds & More

Audit of Laurus Labs completed by USFDA without objections

The maiden United States Food and Drug Administration (USFDA) audit for Laurus Labs was successfully completed without Form 483 .

Jul 12, 2019, 05.47 PM IST
Laurus Labs Ltd got its audits approved by USFDA
New Delhi: Drug firm Laurus Labs Friday said audit of its unit 4 at Visakhapatnam in Andhra Pradesh by the US health regulator has been completed without any observations.

"The inspection of the unit 4 was carried out from July 8 - 12, 2019," Laurus Labs said in a filing to BSE.

The maiden United States Food and Drug Administration (USFDA) audit for the unit was successfully completed without any observations and no Form 483 was issued, it added.

As per the USFDA, Form 483 notifies the company's management of objectionable conditions.

Shares of Laurus Labs were trading at Rs 354.05 per scrip on BSE, up 2.34 per cent from the previous close.


Also Read

USFDA concludes inspection of Unichem Lab's Roha facility

USFDA finds Salmonella bacteria in MDH sambar masala

USFDA completes inspection of Strides Pharma Bengaluru plant

Glenmark gets USFDA nod for plaque psoriasis treatment drug

Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.

Other useful Links

Follow us on

Download et app

Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service